Advanced search
Publication Cover
Hematology Volume 28, 2023 - Issue 1
Submit an article Journal homepage
803
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Application of peripherally inserted central catheter in immune tolerance induction treatment of children with hemophilia A and accompanying inhibitors in China

Chunli Wanga Nursing Department, Beijing Children’s Hospital, Capital Medical University, Beijing, People’s Republic of China;b National Center for Children’s Health, Beijing, People’s Republic of ChinaView further author information
,
Guoqing Liub National Center for Children’s Health, Beijing, People’s Republic of China;c Beijing Key Laboratory of Pediatric Hematology Oncology, Hematology Center, Beijing, People’s Republic of China;d National Key Discipline of Pediatrics, Capital Medical University, Beijing, People’s Republic of China;e Ministry of Education, Key Laboratory of Major Diseases in Children, Beijing, People’s Republic of China;f Department II of Hematology Center, Haemophilia Comprehensive Care Center, Beijing Children’s HospitalCapital Medical University, Beijing, People’s Republic of ChinaView further author information
,
Yaguang Dinga Nursing Department, Beijing Children’s Hospital, Capital Medical University, Beijing, People’s Republic of China;b National Center for Children’s Health, Beijing, People’s Republic of ChinaView further author information
,
Zekun Lib National Center for Children’s Health, Beijing, People’s Republic of China;c Beijing Key Laboratory of Pediatric Hematology Oncology, Hematology Center, Beijing, People’s Republic of China;d National Key Discipline of Pediatrics, Capital Medical University, Beijing, People’s Republic of China;e Ministry of Education, Key Laboratory of Major Diseases in Children, Beijing, People’s Republic of China;f Department II of Hematology Center, Haemophilia Comprehensive Care Center, Beijing Children’s HospitalCapital Medical University, Beijing, People’s Republic of ChinaView further author information
,
Yingzi Zhena Nursing Department, Beijing Children’s Hospital, Capital Medical University, Beijing, People’s Republic of China;b National Center for Children’s Health, Beijing, People’s Republic of ChinaView further author information
,
Jie Cuia Nursing Department, Beijing Children’s Hospital, Capital Medical University, Beijing, People’s Republic of China;b National Center for Children’s Health, Beijing, People’s Republic of ChinaView further author information
,
Wanru Yaob National Center for Children’s Health, Beijing, People’s Republic of China;c Beijing Key Laboratory of Pediatric Hematology Oncology, Hematology Center, Beijing, People’s Republic of China;d National Key Discipline of Pediatrics, Capital Medical University, Beijing, People’s Republic of China;e Ministry of Education, Key Laboratory of Major Diseases in Children, Beijing, People’s Republic of China;f Department II of Hematology Center, Haemophilia Comprehensive Care Center, Beijing Children’s HospitalCapital Medical University, Beijing, People’s Republic of ChinaView further author information
,
Ai Dib National Center for Children’s Health, Beijing, People’s Republic of China;c Beijing Key Laboratory of Pediatric Hematology Oncology, Hematology Center, Beijing, People’s Republic of China;d National Key Discipline of Pediatrics, Capital Medical University, Beijing, People’s Republic of China;e Ministry of Education, Key Laboratory of Major Diseases in Children, Beijing, People’s Republic of China;f Department II of Hematology Center, Haemophilia Comprehensive Care Center, Beijing Children’s HospitalCapital Medical University, Beijing, People’s Republic of ChinaView further author information
,
Kun Huangb National Center for Children’s Health, Beijing, People’s Republic of China;c Beijing Key Laboratory of Pediatric Hematology Oncology, Hematology Center, Beijing, People’s Republic of China;d National Key Discipline of Pediatrics, Capital Medical University, Beijing, People’s Republic of China;e Ministry of Education, Key Laboratory of Major Diseases in Children, Beijing, People’s Republic of China;f Department II of Hematology Center, Haemophilia Comprehensive Care Center, Beijing Children’s HospitalCapital Medical University, Beijing, People’s Republic of ChinaView further author information
,
Ping Fenga Nursing Department, Beijing Children’s Hospital, Capital Medical University, Beijing, People’s Republic of China;b National Center for Children’s Health, Beijing, People’s Republic of ChinaView further author information
&
Runhui Wub National Center for Children’s Health, Beijing, People’s Republic of China;c Beijing Key Laboratory of Pediatric Hematology Oncology, Hematology Center, Beijing, People’s Republic of China;d National Key Discipline of Pediatrics, Capital Medical University, Beijing, People’s Republic of China;e Ministry of Education, Key Laboratory of Major Diseases in Children, Beijing, People’s Republic of China;f Department II of Hematology Center, Haemophilia Comprehensive Care Center, Beijing Children’s HospitalCapital Medical University, Beijing, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Article: 2250601 | Received 19 Oct 2022, Accepted 04 Jan 2023, Published online: 07 Sep 2023

References

  • Bedoya MA, Raffini L, Durand R, et al. Implantable venous access devices in children with severe hemophilia: a tertiary pediatric institutional experience. Pediatr Radiol. 2020;50(8):1148–1155.
  • Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol. 1996;92:973–978.
  • Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. Am J Hematol. 1998;59:288–294.
  • Escuriola C, Kreuz W. The immune tolerance induction(ITI) dose debate: does the international ITI study provide a clearer picture? Haemophilia. 2013;19(1):12–17.
  • Marijke van den Berg H, et al. Different impact of factor VIII products on inhibitor development. Thromb J. 2016;14(1):31–31.
  • Baojun S, Shiwei Y, Pingchong L, et al. Clinical study on factor VIII inhibitor in children with hemophilia A. Chinese J Hematol. 2020;41(2):138–142.
  • Thrombosis and hemostasis group of hematology branch of Chinese medical association, Chinese hemophilia cooperation group. Chinese guideline to hemophilia treatment (2020 edition). Chinese J Hematol. 2020;41(4):265–271.
  • Rocino A, Franchini M, Coppola A. Treatment and prevention of bleeds in haemophilia patients with inhibitors to factor VIII/IX. J Clin Med. 2017;6:46–52.
  • Kulkarni R, Presley RJ, Lusher JM, et al. Complications of haemophilia in babies (first two years of life): a report from the centers for disease control and prevention universal data collection system. Haemophilia. 2016;23:207–214.
  • Ewenstein BM, Valentino LA, Journeycake JM, et al. Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia. 2004;10:629–648.
  • Veps LK, Lassila R, Arola M, et al. Complications associated with central venous access device in children with haemophilia: a nationwide multicentre study in Finland. Haemophilia Official J World Feder Hemophilia. 2015;21(6):747–753.
  • Langley AR, Stain AM, Chan A, et al. Experience with central venous access devices (CVADs) in the Canadian hemophilia primary prophylaxis study (CHPS). Haemophilia. 2015;21(4):469–476.
  • Adriana F, Kim N, Kay D, et al. Central venous access device insertion and perioperative management of patients with severe haemophilia A: a local experience. Blood Coagul Fibrinol. 2016;27:156–159.
  • Hedi B, Maud M, Alexandre T, et al. Outpatient central venous access device insertion in very young children with severe haemophilia. Blood Coagulation and Fibrinolysis. 2020;31:490–499.
  • Santagostino E, Mancuso ME. Venous access in haemophilic children: choice and management. Haemophilia. 2010;16(1):20–24.
  • Titapiwatanakun R, Moir C, Pruthi RK, et al. Central venous access devices for paediatric patients with haemophilia: a singleinstitution experience. Haemophilia. 2009;15:168–174.
  • Nogami K, Taki M, Matsusuhita T, et al. The Japanese immune tolerance induction(J-ITI) study in haemophilia patients with inhibitor: outcomes and successful predictors of ITI treatment. Haemophilia. 2018;24:328–337.
  • Lenk H, Group ITTS. The German registry of immune tolerance treatment in hemophilia–1999 update. Haematologica. 2000;85(Suppl. 10):45–47.
  • Dimichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia. 2002;8(3):280–287.
  • Zekun L, Zhenping C, Guoqing L, et al. Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors. Res Pract Thromb Haemost. 2021;5:125–162.
  • Delarbre B, Dabadie A, Stremler N, et al. Introduction of the of a pediatric PICC line in a French university hospital: review of the first 91 procedures. Diagn Interv Imaging. 2014;95:277–281.
  • Khair K, Ranta S, Thomas A, et al. The impact of clinical practice on the outcome of central venous access devices in children with haemophilia. Haemophilia. 2017;23:e276–e281.
  • Buckley B, Dreyfus J, Prasad M, et al. Burden of illness and costs among paediatric haemophilia patients with and without central venous access devices treated in US hospitals. Haemophilia Official J World Feder Hemophilia. 2018;24(3):e93–e102.
  • Globe DR, Curtis RG, Koerper MA, et al. Utilization of care in haemophilia: a resource- based method for cost analysis from the Haemophilia Utilization Group Study (HUGS). Haemophilia. 2004;10(Suppl. 1):63–70.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.